What question did this study set out to answer?

Compare the effects of artemether-lumefantrine and dihydroartemisinin-piperaquine on gametocyte carriage, mosquito infectivity, and recurrent parasitemia in children with uncomplicated falciparum malaria.

March 6, 2013The Journal of Infectious DiseasesOpen Access

Malaria Transmission After Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine: A Randomized Trial

View Full Paper

Ask AI

Bookmark

Authors

PSPatrick SawaInternational Centre of Insect Physiology and Ecology SSSeif ShekalagheMinistry of Health and Social Welfare CDChris DrakeleyStatens Serum Institut

Discussion

Member takes

Implication

Randomized trial reveals lower gametocyte carriage and infectivity with artemether-lumefantrine in children with malaria, indicating distinct transmission-blocking advantages between therapies.

Key Points

Compare the effects of artemether-lumefantrine and dihydroartemisinin-piperaquine on gametocyte carriage, mosquito infectivity, and recurrent parasitemia in children with uncomplicated falciparum malaria.
Randomized trial (NCT00868465) conducted in Mbita, Kenya, enrolling 298 children aged 6 months to 10 years with uncomplicated falciparum malaria assigned to artemether-lumefantrine (n=153) or dihydroartemisinin-piperaquine (n=145).
Gametocyte carriage was monitored by molecular assays on days 0, 1, 2, 3, 7, 14, 28, and 42, and transmission potential was evaluated on day 7 using direct membrane mosquito-feeding assays.
Cumulative risk of recurrent parasitemia at day 42 (unadjusted for PCR) was 20.7% (95% CI, 14.4–28.2) for artemether-lumefantrine compared with 3.7% (95% CI, 1.2–8.5) for dihydroartemisinin-piperaquine (P < .001).
Mean duration of gametocyte carriage was 5.5 days (95% CI, 3.6–8.5) with artemether-lumefantrine versus 15.3 days (95% CI, 9.7–24.2) with dihydroartemisinin-piperaquine (P = .001).
Mosquito infection rates at day 7 were 1.88% (43 of 2,293) after feeding on blood from artemether-lumefantrine recipients versus 3.50% (83 of 2,371) for dihydroartemisinin-piperaquine (P = .06), with significantly lower oocyst burden in the artemether-lumefantrine group (P = .005).

Cite This Study

Sawa et al. (2013) studied this question.

synapsesocial.com/papers/6a71466eac440176ef29f2df https://doi.org/10.1093/infdis/jit077

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial reveals lower gametocyte carriage and infectivity with artemether-lumefantrine in children with malaria, indicating distinct transmission-blocking advantages between therapies.

Malaria Transmission After Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine: A Randomized Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Malaria Transmission After Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine: A Randomized Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider